ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 963

Long-Term Safety of Tofacitinib up to 9.5 Years: A Comprehensive Integrated Analysis of the RA Clinical Development Program

Stanley Cohen1, Yoshiya Tanaka2, Xavier Mariette3, Jeffrey R. Curtis4, Eun Bong Lee5, Peter Nash6, Kevin Winthrop7, Christina Charles-Schoeman8, Lisy Wang9, Connie Chen10, Kenneth Kwok10, Pinaki Biswas10, Andrea Shapiro11, Ann Madsen10 and Jürgen Wollenhaupt12, 1Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, 2University of Occupational and Environmental Health, Kitakyushu, Japan, 3Paris-Sud University, Le Kremlin Bicêtre, France, 4University of Alabama at Birmingham, Birmingham, AL, 5Seoul National University, Seoul, Korea, Republic of (South), 6University of Queensland, Brisbane, Australia, 7Oregon Health and Science University, Portland, OR, 8University of California, Los Angeles, CA, 9Pfizer Inc, Groton, CT, 10Pfizer Inc, New York, NY, 11Pfizer Inc, Peapack, NJ, 12Schön-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: clinical trials, DMARDs, rheumatoid arthritis, safety and tofacitinib, treatment

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Session Title: 3S108 ACR Abstract: RA–Treatments II: Safety (958–963)

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Here, we report the largest integrated safety analysis of tofacitinib to date using data from Phase (P)1, P2, P3, P3b/4, and open-label long-term extension (LTE) studies in adult patients (pts) with RA.

Methods: Data were pooled for pts who received ≥1 tofacitinib dose, as monotherapy or with background conventional synthetic DMARDs (csDMARDs), integrated across 2 P1, 10 P2, 6 P3, 1 P3b/4, and 2 LTE studies (ORAL Sequel LTE main study database locked at time of analysis: March 2017). Incidence rates (IR; pts with events per 100 patient-years [PY]) and 95% confidence intervals were obtained for safety events of special interest. Additionally, IRs for deep vein thrombosis (DVT) and pulmonary embolism (PE) are reported. IRs were based on the number of pts with incident events during the time between the first and last dose plus 28 days, which was the clinical trial observation period (previous analyses included events outside of the observation period).

Results: This analysis included 7061 pts, representing 22,875 PY of tofacitinib exposure, with a median exposure of 3.1 years, and 30% of pts had >5 years of exposure. A total of 1634 (23.1%) pts discontinued due to adverse events (AEs; IR: 7.1 [6.8, 7.5]). The most common treatment-emergent AEs by MedDRA v20.0 preferred term were viral upper respiratory tract infection (17.3%), upper respiratory tract infection (17.2%), and urinary tract infection (11.8%). The IR for serious AEs was 9.0 (8.6, 9.4), of which infections were the most common. Serious infections occurred in 576 pts (8.2%; IR: 2.5 [2.3, 2.7]), and pneumonia was the most frequently reported serious infection (124 pts [22% of all pts with serious infections]). Overall, 782 pts (11.1%) developed herpes zoster (HZ; IR: 3.6 [3.4, 3.9]); in most pts HZ involved a single dermatome (90.2%). Serious HZ was reported in 57 pts (7.3% of all pts with HZ). Opportunistic infections (excluding tuberculosis [TB]) were reported in 90 pts (1.3%; IR: 0.4 [0.3, 0.5]) and TB was reported in 38 pts (0.5%; IR: 0.2 [0.1, 0.2]). Malignancies (excluding non-melanoma skin cancer [NMSC]) occurred in 177 pts (2.5%; IR: 0.8 [0.7, 0.9]), NMSC in 129 pts (1.8%; IR: 0.6 [0.5, 0.7]) and lymphomas in 12 pts (0.2%; IR: 0.1 [0.0, 0.1]). Gastrointestinal perforations were reported in 28 pts (0.4%; IR: 0.1 [0.1, 0.2]) and major adverse cardiovascular events in 85 pts (1.3%; IR: 0.4 [0.3, 0.5]). DVT was reported in 27 pts (0.4%; IR: 0.12 [0.08, 0.17]) and PE in 28 pts (0.4%; IR: 0.12 [0.08, 0.17]). There were 59 deaths (0.8%; IR: 0.3 [0.2, 0.3]). IRs for AEs of interest were stable across 6-month intervals.

Conclusion: This long-term integrated safety analysis with up to 9.5 years of follow-up and 22,875 PY of tofacitinib exposure represents one of the largest clinical datasets to date for an advanced RA treatment. The safety profile of tofacitinib remained consistent with those of previous randomized controlled trials in the RA clinical development program.

 


Disclosure: S. Cohen, Pfizer Inc, 2,Pfizer Inc, 5; Y. Tanaka, AbbVie, Astellas, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, Mitsubishi-Tanabe, MSD, Ono, Taisho-Toyama, Takeda, 2,AbbVie, Asahi-Kasei, Astellas, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, GSK, Janssen, Mitsubishi-Tanabe, Novartis, Pfizer Inc, Sanofi, Takeda, UCB, YL Biologics, 8; X. Mariette, Pfizer Inc, 2,Bristol-Myers Squibb, Janssen, Pfizer Inc, UCB, 5; J. R. Curtis, AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, Roche, UCB, 2,AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, Roche, UCB, 5; E. B. Lee, Green Cross Pharma, 2,Eli Lilly, Pfizer Inc, 5,Korean Health Insurance Review and Assessment Service, 6; P. Nash, AbbVie, Bristol-Myers Squibb, Eli Lilly, Janseen, Novartis, Pfizer Inc, Roche, Sanofi, UCB, 2,AbbVie, Bristol-Myers Squibb, Eli Lilly, Janseen, Novartis, Pfizer Inc, Roche, Sanofi, UCB, 5,AbbVie, Bristol-Myers Squibb, Eli Lilly, Janseen, Novartis, Pfizer Inc, Roche, Sanofi, UCB, 8; K. Winthrop, Bristol-Mysers Squibb, 2; C. Charles-Schoeman, AbbVie, Pfizer Inc, 2,Gilead, Pfizer Inc, Sanofi, 5; L. Wang, Pfizer Inc, 1,Pfizer Inc, 3; C. Chen, Pfizer Inc, 1,Pfizer Inc, 3; K. Kwok, Pfizer Inc, 1,Pfizer Inc, 3; P. Biswas, Pfizer Inc, 1,Pfizer Inc, 3; A. Shapiro, Pfizer Inc, 1,Pfizer Inc, 3; A. Madsen, Pfizer Inc, 1,Pfizer Inc, 3; J. Wollenhaupt, Pfizer Inc, 1,Pfizer Inc, 5,Pfizer Inc, 8.

To cite this abstract in AMA style:

Cohen S, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop K, Charles-Schoeman C, Wang L, Chen C, Kwok K, Biswas P, Shapiro A, Madsen A, Wollenhaupt J. Long-Term Safety of Tofacitinib up to 9.5 Years: A Comprehensive Integrated Analysis of the RA Clinical Development Program [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/long-term-safety-of-tofacitinib-up-to-9-5-years-a-comprehensive-integrated-analysis-of-the-ra-clinical-development-program/. Accessed February 3, 2023.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-safety-of-tofacitinib-up-to-9-5-years-a-comprehensive-integrated-analysis-of-the-ra-clinical-development-program/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences